1、Re-inventing Pharma with Artificial IntelligenceThree steps for pharmaceutical companies to seize the$250bn AI value potential in the future of healthContactsAustriaMatthias SchlemmerPartner,Strategy&Austria+43-664-5152-GermanyDr.Christian KasparPartner,Strategy&Germany+49-170-9362-Dr.Jens NeumannPa

2、rtner,Strategy&Germany+49-172-2337/Dr.Thomas SolbachPartner,Strategy&Germany+49-170-2238-SwitzerlandMatthias LeyboldPartner,PwC Switzerland+41-58-792-1396matthias.leyboldpwc.chUnited KingdomColin LightPartner,Strategy&UK+44-7782-329-Thalita MarinhoPartner,Strategy&UK+44-7900-163-United StatesRonald

3、ChopoorianPartner,PwC United States+1-973-449-Philip SclafaniPartner,PwC United States+1-631-767-About the authorsDr.Christian Kaspar is a partner with Strategy&Germany leading the Digital and Technology Strategy practice in Europe.Based in Munich,he advises clients in the pharma,MedTech and healthc

4、are industries on IT transformation projects,technology innovations,as well as data and AI strategies.Dr.Thomas Solbach advises clients in the healthcare and life sciences industry globally.He leads the pharma and life sciences practice at Strategy&Europe.Based in Frankfurt,he is a partner with Stra

5、tegy&Germany.Hans-Fabian Ahrens is a manager with Strategy&Germany,based in Hamburg.He supports clients predominantly within the pharma-ceutical sector around technology,data,analytics,and AI strategies.Johannes Dizinger is a manager with Strategy&Switzerland and is based in Zurich.His expertise lie

6、s at the intersection of pharma and life sciences,technology,data analytics,AI and digital strategy.Jonathan Mller is a manager with Strategy&Germany.Based in Hamburg,his focus topics include data-driven transformation and business model innovation,particularly in the life sciences and digital healt